All New TrueVue in Far East as Deltex Exhibits at KIMES 2024
New haemodynamic monitoring system on show at Korean Medtech Exhibition:
British manufacturer and world expert in haemodynamic monitoring systems, Deltex Medical is delighted to be attending this years Korea International Medical & Hospital Equipment Show (KIMES 2024) in Seoul, March 14-17. For Deltex the event is another opportunity to showcase its new TrueVue haemodynamic monitoring system, which represents a major milestone for the company.
Deltex is appearing on the UK pavilion (Hall D, booth number D316) at KIMES 2024 and is being supported by the UK’s Department of Business and Trade.
Haemodynamic monitoring for a new era
New TrueVue represents the biggest raft of changes Deltex has undertaken since oesophageal Doppler monitoring first hit the headlines over 10 years ago. The new product delivers the proven benefits of oesophageal Doppler monitoring (ODM) in a system that is now easier-to-use and designed for a new generation of users. In reality the new system is built almost entirely to address feedback from the anaesthesiologist community. The new TrueVue haemodynamic monitoring platform features an intuitive HD touchscreen and optional battery power. This means it can continue to guide interventions during the critical stages of the patient pathway. Coupled with improvements in signal acquisition and maintenance, clinicians are now better able to deliver the proven benefits of Doppler monitoring to more patients. All new TrueVue represents a highly significant milestone on Deltex’s mission to eliminate complications caused by haemodynamic instability.
“Mission: Zero complications from haemodynamic causes, in our sights” says Deltex CEO
Deltex, CEO Andy Mears states; “Faced with high pressure operating and critical care environments it’s tempting for clinicians to think of haemodynamic monitoring as a luxury. However the evidence tells us that outcomes are significantly improved if the patient is in an optimum haemodynamic state. Only TrueVue with its unique oesophageal Doppler monitoring (ODM) technology is accurate and powerful enough to deliver the real-time information anaesthesiologists need to guide their fluid and drug interventions. Now even easier to use and portable between clinical settings, the patient benefits are within reach. This means better outcomes, increased efficiency and lower costs.”
He adds; ”We’re grateful and honoured to be supported by the UK’s Department of Business and Trade as we endeavour to extend the reach and impact of our leading technology.”
